EUCTR2012-001644-21-DE进行中（未招募）不适用
MEA115661: A multi-centre, open-label, long-term safety study of mepolizumab in asthmatic subjects who participated in the MEA115588 or MEA115575 trials.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 651
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Informed Consent: Prior to commencing any study related activities, subjects must be able and willing to provide written informed consent.
- •2. MEA115588 or MEA11575 study completion: Completion of the double-blind investigational product treatment during MEA115588 or MEA11575.
- •3. Current Anti-Asthma Therapy: Asthma is currently being treated with a controller medication (i.e., ICS or other asthma controlled medication) and the subject has been on a controller therapy through the end of MEA115588 or MEA115575. Subjects will be expected to continue controller therapy for the duration of the study.
- •4. Male or eligible female subjects:
- •5. To be eligible for entry into the study, females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control (Appendix 2) for the duration of the trial and for 4 months after the last study drug administration.
- •6. A serum pregnancy test is required of all females of childbearing potential at the initial Baseline Visit (Visit 1). In addition, a urine pregnancy test will be performed for all females of childbearing potential prior to enrollment, during each scheduled study visit prior to the injection of investigational product, and during the Follow-up Visit.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 20
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 522
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 113
排除标准
- •1. Hypersensitivity: Hypersensitivity reaction related to study medication during the MEA115588 or MEA115575 that led to patient withdrawal. Subjects who experienced a localized injection site reaction do not need to be excluded.
- •2. Health Status: Clinically significant change in health status during MEA115588 or MEA115575 which in the opinion of the investigator would make the subject unsuitable for participation in this long-term study.
- •3. Malignancy: A current malignancy or malignancy that developed during
- •MEA115588 or MEA115575 (subjects that had localized carcinoma of the skin which was resected for cure will not be excluded). [Note for South Korea: Korean subjects with a diagnosis of malignancy within 5 years are excluded]
- •4. Prior SAE: A study related SAE in MEA115588 or MEA115575 that was assessed as possibly related to study medication by the investigator.
- •5. Pregnancy: Subjects who are pregnant or breastfeeding. Subjects should not be enrolled if they plan to become pregnant during the time of study participation.
- •6. ECG: Baseline ECG which has a clinically significant abnormality or which shows QTcF =450msec or QTcF =480msec for subjects with Bundle Branch Block.
- •7. Smoking status: Current smokers
研究者
相似试验
进行中（未招募）
不适用
A safety study for subjects with severe asthma who participated in MEA115575 or MEA115588Subjects with Severe AsthmaMedDRA version: 16.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2012-001644-21-GBGlaxoSmithKline Research & Development Ltd651
进行中（未招募）
不适用
A safety study for subjects with severe asthma who participated in MEA115575 or MEA115588Subjects with Severe AsthmaEUCTR2012-001644-21-NLGlaxoSmithKline Research & Development Ltd660
进行中（未招募）
不适用
A safety study for subjects with severe asthma who participated in MEA115575 or MEA115588Subjects with Severe Asthma.MedDRA version: 15.1Level: LLTClassification code 10068462Term: Eosinophilic asthmaSystem Organ Class: 100000004855EUCTR2012-001644-21-ESGlaxoSmithKline, S.A.660
已完成
3 期
MEA115661: A multi-centre, open-label, long-term safety study of mepolizumab in asthmatic subjects who participated in the MEA115588 or MEA115575 trials10006436bronchial asthmaasthmaNL-OMON39006GlaxoSmithKline BV27
进行中（未招募）
不适用
A safety study for subjects with severe asthma who participated in MEA115575 or MEA115588EUCTR2012-001644-21-CZGlaxoSmithKline Research & Development Ltd651